全文获取类型
收费全文 | 130137篇 |
免费 | 10252篇 |
国内免费 | 4766篇 |
专业分类
耳鼻咽喉 | 1563篇 |
儿科学 | 2140篇 |
妇产科学 | 2010篇 |
基础医学 | 17049篇 |
口腔科学 | 2899篇 |
临床医学 | 14320篇 |
内科学 | 22480篇 |
皮肤病学 | 2267篇 |
神经病学 | 9024篇 |
特种医学 | 5711篇 |
外国民族医学 | 21篇 |
外科学 | 14391篇 |
综合类 | 12358篇 |
现状与发展 | 28篇 |
一般理论 | 52篇 |
预防医学 | 8836篇 |
眼科学 | 3164篇 |
药学 | 12158篇 |
67篇 | |
中国医学 | 3998篇 |
肿瘤学 | 10619篇 |
出版年
2024年 | 174篇 |
2023年 | 1131篇 |
2022年 | 2675篇 |
2021年 | 4588篇 |
2020年 | 3201篇 |
2019年 | 3252篇 |
2018年 | 3672篇 |
2017年 | 3406篇 |
2016年 | 3750篇 |
2015年 | 5041篇 |
2014年 | 6391篇 |
2013年 | 7101篇 |
2012年 | 10515篇 |
2011年 | 11143篇 |
2010年 | 7081篇 |
2009年 | 6226篇 |
2008年 | 8361篇 |
2007年 | 8368篇 |
2006年 | 7719篇 |
2005年 | 7241篇 |
2004年 | 6031篇 |
2003年 | 5807篇 |
2002年 | 5084篇 |
2001年 | 2107篇 |
2000年 | 1757篇 |
1999年 | 1738篇 |
1998年 | 1356篇 |
1997年 | 1160篇 |
1996年 | 1006篇 |
1995年 | 893篇 |
1994年 | 823篇 |
1993年 | 655篇 |
1992年 | 610篇 |
1991年 | 574篇 |
1990年 | 499篇 |
1989年 | 484篇 |
1988年 | 371篇 |
1987年 | 353篇 |
1986年 | 317篇 |
1985年 | 309篇 |
1984年 | 238篇 |
1983年 | 206篇 |
1982年 | 231篇 |
1981年 | 189篇 |
1980年 | 166篇 |
1979年 | 128篇 |
1978年 | 129篇 |
1977年 | 134篇 |
1976年 | 99篇 |
1975年 | 114篇 |
排序方式: 共有10000条查询结果,搜索用时 15 毫秒
61.
62.
OBJECTIVES: To assess the effectiveness and safety of additional bedtime H2‐receptor antagonists (H2RAs) in suppressing nocturnal gastric acid breakthrough (NAB) via a systematic review. METHODS: Eligible trials were identified by searching the Cochrane Central Register of Controlled Trials (CENTRAL) (Cochrane Library Issue 2, 2004), MEDLINE (January 1966–June 2004), EMBASE (January 1980–June 2004) and CINAHL (January 1982–June 2004). Additional hand‐searching was conducted on the proceedings of correlated conferences, eight important Chinese journals and references of all included trials. All randomized controlled trials evaluating H2RAs for the control of NAB were eligible for inclusion. The systematic review was conducted using methods recommended by The Cochrane Collaboration. RESULTS: Only two randomized crossover studies, comprising 32 participants, met the inclusion criteria. Because the design, dosage and duration of the treatments were different between the studies, it was not possible to conduct meta‐analysis. There were no consistent conclusions found between the two included studies in evaluating H2RAs for the control of NAB. CONCLUSIONS: No implications for practice at this stage can be concluded. Appropriately designed large‐scale randomized controlled trials with long‐term follow up are needed to determine the effects of additional bedtime H2RAs in suppressing NAB. 相似文献
63.
Factors predicting tracer uptake in somatostatin receptor and MIBG scintigraphy of metastatic gastroenteropancreatic neuroendocrine tumors. 总被引:1,自引:0,他引:1
Samer Ezziddin Timur Logvinski Charlotte Yong-Hing Hojjat Ahmadzadehfar Hans-Peter Fischer Holger Palmedo Jan Bucerius Michael J Reinhardt Hans-Jürgen Biersack 《Journal of nuclear medicine》2006,47(2):223-233
Radiolabeled octreotide analogs (Oct) and metaiodobenzylguanidine (MIBG) offer 2 different approaches for imaging and targeting metastatic gastroenteropancreatic neuroendocrine tumors (GEP-NET). Despite successful establishment of the revised World Health Organization (WHO) classification, which distinguishes between low- and high-grade malignant GEP-NET, there is a lack of scintigraphic studies comparing uptake behavior on the basis of this categorization. This study aims to define predisposing factors of tracer uptake for both imaging principles implementing the updated tumor criteria of the current WHO classification. METHODS: Fifty-seven consecutive patients with histologically confirmed metastatic GEP-NET evaluated with both 111In-pentetreotide and 123I/131I-MIBG scintigraphy were included in this study. Intensity of tracer uptake was graded according to the different metastatic regions. Patients were classified as overall positive when avid uptake in the clinically relevant tumor lesions was present. Correlation was tested between the proportion of positive patients and tumor origin, function, and malignancy. RESULTS: Overall, 52 patients (91.2%) were Oct positive and 28 patients (49.1%) were MIBG positive. The proportion of tracer-positive patients was significantly higher (P < 0.05) in low-grade malignant tumors for both tracers and in functioning as well as in gastroenteral NET for MIBG. Five patients were negative for both tracers. None of the Oct-negative patients proved to be MIBG positive. CONCLUSION: Oct affinity is observed with high frequency throughout the subgroups of metastatic GEP-NET, whereas corresponding MIBG uptake is overall less prevalent and more group dependent. Tumor differentiation significantly impacts both Oct and MIBG uptake, whereas functionality predisposes only for MIBG accumulation. Though clearly inferior to Oct-based radioimaging in most GEP-NET, MIBG achieves a remarkable rate of radioligand accumulation in functioning midgut enterochromaffin cell metastases (>80% of patients positive). These results may have implications for patient management and potentially for selection and performance of targeted therapy. 相似文献
64.
Jan Jozef Braszko Anna Walesiuk Przemyslaw Wielgat 《Journal of the renin-angiotensin-aldosterone system》2006,7(3):168-174
This study tests the hypothesis that the facilitation of learning and improvement of memory observed after an intracerebroventricular (i.c.v.) injection of angiotensin II (Ang II) is, in fact, caused by its derivative angiotensin IV (Ang IV). We ran two memory tests as well as an auxiliary test assessing motor performance in rats injected (i.c.v., 1 nmol in 2 microl saline) with Ang II or Ang IV. There were separate groups receiving peptide or saline five, 10 and 15 minutes before testing. Ang IV significantly increased step-through latencies in a passive avoidance paradigm as well as improved discrimination between familiar and unfamiliar objects in an object recognition test in all groups showing better retrieval of memory of aversive as well as appetitive stimuli in the peptide-treated groups regardless of the time of its injection. In contrast, rats treated with Ang II demonstrated significant improvement of memory of aversive and appetitive stimuli in the same tests only 15 minutes after its i.c.v. injection, with no effect in the groups injected five minutes before testing and slight efficacy in those injected 10 minutes before the test. Numbers of crossings, rearings and bar approaches in an open field were similar both in the peptide-treated and control groups making it unlikely that changes in motor performance affected the memory tests. In line with the present views on the intracellular metabolism of Ang II, these results suggest degradation to Ang IV by aminopeptidases A and N is necessary before the cognitive effects can occur. 相似文献
65.
66.
Kei Kamide Yoshihiro Kokubo Hironori Hanada Junko Nagura Jin Yang Shin Takiuchi Chihiro Tanaka Mariko Banno Yoshikazu Miwa Masayoshi Yoshii Tetsutaro Matayoshi Hisayo Yasuda Takeshi Horio Akira Okayama Hitonobu Tomoike Yuhei Kawano Toshiyuki Miyata 《Hypertension research》2006,29(4):243-252
Mutations in the gene encoding 11beta-hydroxysteroid dehydrogenase type 2, HSD11B2, cause a rare monogenic juvenile hypertensive syndrome called apparent mineralocorticoid excess (AME). In AME, defective HSD11B2 enzyme activity results in overstimulation of the mineralocorticoid receptor (MR) by cortisol, causing sodium retention, hypokalemia, and salt-dependent hypertension. Here, we have studied whether genetic variations in HDS11B2 are implicated in essential hypertension in Japanese hypertensives and the general population. By sequencing the entire coding region and the promoter region of HDS11B2 in 953 Japanese hypertensives, we identified five missense mutations in 11 patients (L14F, n = 5; R74H, n = 1; R147H, n = 3; T156I, n = 1; R335H, n = 1) and one novel frameshift mutation (4884Gdel, n = 1) in a heterozygous state, in addition to 19 genetic variations. All genetic variations identified were rare, with minor allele frequencies less than 0.005. Four of 12 patients with the missense/frameshift mutations showed renal failure. Four missense mutations, L14F, R74H, R147H, and R335H, were successfully genotyped in the general population, with a sample size of 3,655 individuals (2,175 normotensives and 1,480 hypertensives). Mutations L14F, R74H, R147H, and R335H were identified in hypertensives (n = 6, 8, 3, and 0, respectively) and normotensives (n = 8, 12, 5, and 0, respectively) with a similar frequency, suggesting that these missense mutations may not strongly affect the etiology of essential hypertension. Since the allele frequency of all of the genetic variations identified in this study was rare, an association study was not conducted. Taken together, our results indicate that missense mutations in HSD11B2 do not substantially contribute to essential hypertension in Japanese. 相似文献
67.
M J Barbanoj R M Antonijoan J Riba M Valle S Romero F Jané 《Clinical EEG and neuroscience》2006,37(2):108-120
A drug interaction refers to an event in which the usual pharmacological effect of a drug is modified by other factors, most frequently additional drugs. When two drugs are administered simultaneously, or within a short time of each other, an interaction can occur that may increase or decrease the intended magnitude or duration of the effect of one or both drugs. Drugs may interact on a pharmaceutical, pharmacokinetic or pharmacodynamic basis. Pharmacodynamic interactions arise when the alteration of the effects occurs at the site of action. This is a wide field where not only interactions between different drugs are considered but also drug and metabolites (midazolam/alpha-hydroxy-midazolam), enantiomers (ketamine), as well as phenomena such as tolerance (nordiazepam) and sensitization (diazepam). Pharmacodynamic interactions can result in antagonism or synergism and can originate at a receptor level (antagonism, partial agonism, down-regulation, up-regulation), at an intraneuronal level (transduction, uptake), or at an interneuronal level (physiological pathways). Alternatively, psychotropic drug interactions assessed through quantitative pharmaco-EEG can be viewed according to the broad underlying objective of the study: safety-oriented (ketoprofen/theophylline, lorazepam/diphenhydramine, granisetron/haloperidol), strictly pharmacologically-oriented (benzodiazepine receptors), or broadly neuro-physiologically-oriented (diazepam/buspirone). Methodological issues are stressed, particularly drug plasma concentrations, dose-response relationships and time-course of effects (fluoxetine/buspirone), and unsolved questions are addressed (yohimbine/caffeine, hydroxizyne/alcohol). 相似文献
68.
应用64层CT一次扫描完成心脏冠脉成像及心功能分析的可行性初步研究 总被引:1,自引:0,他引:1
目的研究64层CT一次扫描同时完成心脏冠脉成像及心功能分析的可行性。方法96例患者均行MSCT心脏成像扫描和MR心脏检查,数据分别按照冠脉成像和心功能分析要求进行重建和后处理,评估。结果1271段冠脉血管中有约99%血管显示清晰,达到诊断要求;心功能分析数据左室舒张末期容积(LVEDV)、左室收缩末期容积(LVESV)、左室每搏输出量(LVSV)、左室射血分数(LVEF)、左室心肌容积(LVMV)与MR相关数据的相关系数分别为0.84、0.91、0.94、0.89、0.88。结论MSCT可以在一次扫描中完成冠脉成像和心功能数据采集,具有极高应用价值。 相似文献
69.
Eileen Dauer John Salassa Laura Iuga Jan Kasperbauer 《Otolaryngology--head and neck surgery》2006,134(5):830-835
OBJECTIVE: To illustrate the safety and efficacy of the endoscopic laser approach for cricopharyngeal myotomy (CPM) compared to the traditional transcervical approach. STUDY DESIGN AND SETTING: Retrospective chart review of 22 patients undergoing CPM from 1996 to 2003 at the Mayo Clinic, Jacksonville. RESULTS: The laser CPM technique was used in 14 patients, and an open approach in 8. The mean hospital stay and operative times were shorter for the laser group. Functional outcome analyses showed improvement in both groups. There were no major complications in the laser group, while 1 patient in the transcervical group had a pharyngocutaneous fistula. CONCLUSIONS: The laser technique is at least as effective as the transcervical approach for CPM to improve dysphagia symptoms in the properly selected patient, with a low risk of major complications. SIGNIFICANCE: In this report, we provide the reader with data to support the safety and efficacy of laser CPM. EBM rating: B-3b. 相似文献
70.
Johannes Brettschneider Axel Petzold Sigurd D Süssmuth Georg B Landwehrmeyer Albert C Ludolph Jan Kassubek Hayrettin Tumani 《Movement disorders》2006,21(12):2224-2227
We aimed to evaluate the potential of the cerebrospinal fluid (CSF) axonal damage biomarker NfH(SMI35) in the laboratory-supported differential diagnosis of parkinsonian syndromes. Patients with idiopathic Parkinson's disease (PD; n = 22), multiple-system atrophy (MSA; n = 21), progressive supranuclear palsy (PSP; n = 21), corticobasal degeneration (CBD; n = 6), and age-matched controls (n = 45) were included. CSF levels of NfH(SMI35) were measured using ELISA. Levels of CSF NfH(SMI35) were elevated in PSP compared to PD and controls (P < 0.05 each). They were also significantly higher in MSA than in PD and controls (P < 0.05 each). NfH(SMI35) differentiated PD from PSP with a sensitivity of 76.5% and a specificity of 94.4%. Axonal damage as measured by CSF NfH(SMI35) is most prominent in the more rapidly progressive syndromes PSP and MSA as compared to PD or CBD. CSF NfH(SMI35) may therefore be of some value for the laboratory-supported differential diagnosis of atypical parkinsonian syndromes. 相似文献